Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 90.59% is in line with its 5-year average of 93.64%, near the high end of its 5-year range (0.00%–107.10%).
0.06% below its 12-month average of 90.65%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 93.03%.
GROSS MARGIN
90.59%
GROSS MARGIN AVG TTM
90.65%
GROSS MARGIN AVG 3Y
93.05%
GROSS MARGIN AVG 5Y
93.64%
GROSS MARGIN AVG 10Y
N/A
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-0.06%
CURRENT VS 3Y AVG
-2.64%
CURRENT VS 5Y AVG
-3.25%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
41.20%
median of 862 covered companies
CURRENT VS SECTOR MEDIAN
+119.85%
vs the sector median at left
Tarsus Pharmaceuticals, Inc.
Market Cap
$3.19B
Gross Margin
90.59%
TTM Avg
90.65%
3Y Avg
93.05%
5Y Avg
93.64%
Market Cap
$3.12B
Gross Margin
0.00%
TTM Avg
25.88%
3Y Avg
57.90%
5Y Avg
-575.35%
Market Cap
$3.31B
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$3.06B
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
50.00%
5Y Avg
66.67%
Market Cap
$3.03B
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$3.36B
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$3.38B
Gross Margin
91.13%
TTM Avg
91.57%
3Y Avg
93.72%
5Y Avg
94.38%
Market Cap
$2.99B
Gross Margin
91.14%
TTM Avg
90.25%
3Y Avg
87.92%
5Y Avg
58.61%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Tarsus Pharmaceuticals, Inc. (TARS) | $3.19B | 90.59% | 90.65% | 93.05% | 93.64% |
| Amylyx Pharmaceuticals, Inc. (AMLX)vs › | $3.12B | 0.00% | 25.88% | 57.90% | -575.35% |
| CareDx, Inc (CDNA)vs › | $3.30B | 70.58% | 67.35% | 65.86% | 66.29% |
| Viking Therapeutics, Inc. (VKTX)vs › | $3.31B | 0.00% | 0.00% | 0.00% | 0.00% |
| Denali Therapeutics Inc. (DNLI)vs › | $3.06B | 0.00% | 0.00% | 50.00% | 66.67% |
| Enliven Therapeutics, Inc. (ELVN)vs › | $3.03B | 0.00% | 0.00% | 0.00% | 0.00% |
| Parabilis Medicines, Inc. (PBLS)vs › | $3.36B | 0.00% | 0.00% | 0.00% | 0.00% |
| Acadia Pharmaceuticals Inc. (ACAD)vs › | $3.38B | 91.13% | 91.57% | 93.72% | 94.38% |
| Arcutis Biotherapeutics, Inc. (ARQT)vs › | $2.99B | 91.14% | 90.25% | 87.92% | 58.61% |
| Pulse Biosciences, Inc. (PLSE)vs › | $3.44B | -360.00% | -180.00% | -491.57% | -334.18% |
Gross Margin
90.6%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 93.03% |
| 2026-03-31 | 94.20% |
| 2025-12-31 | 92.80% |
| 2025-09-30 | 79.28% |
| 2025-06-30 | 93.92% |
| 2025-03-31 | 93.35% |
| 2024-12-31 | 92.58% |
| 2024-09-30 | 93.26% |
| 2024-06-30 | 92.64% |
| 2024-03-31 | 94.01% |
| 2023-12-31 | 90.70% |
| 2023-09-30 | 79.85% |
| 2023-06-30 | 0.00% |
| 2023-03-31 | 89.80% |
| 2022-12-31 | 96.00% |
| 2022-09-30 | 0.00% |
| 2022-06-30 | 96.58% |
| 2022-03-31 | 93.88% |
| 2021-12-31 | 107.10% |
| 2021-09-30 | 94.76% |
| 2021-06-30 | 96.65% |
| 2021-03-31 | 96.12% |
| 2020-12-31 | 0.00% |
| 2020-09-30 | 0.00% |
| 2020-06-30 | 0.00% |
| 2020-03-31 | 0.00% |
| 2019-12-31 | 0.00% |
| 2019-09-30 | 0.00% |
| 2018-06-30 | 0.00% |
| 2018-03-31 | 0.00% |
